Cat. #160406

Phosphatidylinositol-4-phosphate 5-kinase inhibitor PIP5K Small Molecule (Tool Compound)

Cat. #: 160406

Sub-type: Inhibitor

Availability: Please enquire for quantities and pricing

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Enquire or request a quote

Contributor

Inventor: Martin Swarbrick

Institute: Cancer Research Technology AstraZeneca Metabolism Alliance Team

Tool Details

Handling

Target Details

References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

Tool name: Phosphatidylinositol-4-phosphate 5-kinase inhibitor PIP5K Small Molecule (Tool Compound)
Alternate name: Synonyms for Phosphatidylinositol-4-phosphate 5-kinase: PIKFYVE, Phosphoinositide Kinase, FYVE Finger Containing Phosphatidylinositol-3-Phosphate/Phosphatidylinositol 5-Kinase Type III, Phosphatidylinositol 3-Phosphate 5-Kinase Type III, Type III PIP Kinase, PIPkin-III, PIP5K3, FYVE Finger-Containing Phosphoinositide Kinase 4, 1-Phosphatidylinositol-3-Phosphate 5-Kinase, Phosphatidylinositol 3-Phosphate 5-Kinase, Zinc Finger FYVE Domain Containing, Epididymis Luminal Protein 37, FYVE Domain Containing 29, KIAA981, ZFYVE29, PIKfyve, HEL37, PIP5K, FAB1, CFD
Research fields: Cancer
Tool sub type: Inhibitor
Primary target: Phosphatidylinositol-4-phosphate 5-kinase (PIP5K)
Purpose: Inhibitor
Selectivity: PI4KCA IC50: 20.9 ÂľM PI4KCB IC50: 5.99 ÂľM PI3KÎą IC50: 34.6 ÂľM
Solubility: 15 Ä¾M (Aqueous)
Additional notes: Relevant Indications: PI3K, PLC, Wnt, Fc-receptor, BAF Negative Control Available: No The compounds are made up to 12mM stock concentration in DMSO. The final concentration of DMSO when treating cells should be less than 1%.

Handling

Shipping conditions: Dry Ice

Target Details

Primary target: Phosphatidylinositol-4-phosphate 5-kinase (PIP5K)
Ic50: PIP5KÎą IC50: 0.011 ÂľMPIP5KÎ˛ IC50: 0.004 ÂľMPIP5KÎł IC50: 0.001 ÂľM

References

Andrews et al. 2014. Eur. J. Cancer. 50(6):91